Picture1.jpg
Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency
27 juin 2022 01h00 HE | Curium
Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
Picture1.jpg
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
12 mai 2022 01h05 HE | Curium
ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
Picture1.jpg
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
03 mai 2022 01h05 HE | Curium
ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial.  ECLIPSE is a Phase 3, multi-center, open-label, randomized...
Picture1.jpg
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
19 avr. 2022 01h00 HE | Curium
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
Picture1.jpg
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
05 avr. 2022 01h05 HE | Curium
ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...
Picture1.jpg
Curium to become major player in the supply on non carrier added Lu-177
25 janv. 2022 00h00 HE | Curium
LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...